Recognizing these molecular intricacies, the United States Food and Drug Administration has approved several drugs designed to target at least seven distinct lung cancer mutations [6], alongside NF-κB-targeting therapies [5]. The gene discussed is NFKB1; the disease is lung carcinoma.